Table 1.
Baseline characteristics of the study population (n = 21)
| Sex (n) | |
| Male | 4 |
| Female | 17 |
| Age in years: mean (range) | 87 (70–98) |
| Dementia (n) | |
| Alzheimer’s disease [13] | 5 |
| Vascular dementia (VD) | 4 |
| Mixed dementia (AD/VD) | 3 |
| Frontotemporal dementia | 1 |
| Not otherwise specified | 8 |
| Global Deterioration Scale (n) | |
| 5 = Moderate dementia | 9 |
| 6 = Moderately severe dementia | 10 |
| 7 = Severe dementia | 2 |
| Duration of dementia in months: mean (range) | 53 (3–138) |
| Renal function CKD-EPI: mean ml/min (range) | 65 (35–90) |
| Medical history (n) | |
| Anxiety disorder | 2 |
| Depression | 7 |
| Delirium | 6 |
| Psychotropic medication ATC (n) | |
| Antidepressants | 8 |
| Antipsychotics | 1 |
| Anxiolytics | 6 |
| Hypnotics (benzodiazepines and melatonin) | 7 |
| Anti-epileptics | 0 |
| Anti-dementia medication | 0 |
| Caffeine consumption | |
| Coffee: mean units/day (range) | 4 (2–5) |
| Tea: mean units/day (range) | 1 (0–3) |
| Other: ice tea/energy drink/chocolate > 100 g/week | 0 |